Prostatic incidental uptake on PET/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk - Takeaways - MDSpire

Prostatic incidental uptake on PET/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk

  • By

  • Chiara Martinello

  • Cesare Michele Iacovitti

  • Andreea Marin

  • Slavko Tasevski

  • Alessio Rizzo

  • Marco Cuzzocrea

  • Gaetano Paone

  • Domenico Albano

  • Giorgio Treglia

  • June 22, 2026

  • 0 min

Share

  • 1

    The pooled prevalence of prostatic incidental uptake (PIU) on [18F]FDG PET/CT is 1.7%, while it is 4.5% for PET/CT using somatostatin analogues.

  • 2

    The malignancy rates for PIU cases that underwent further evaluation or biopsy are 21.3% and 59.7%, respectively.

  • 3

    Malignant PIUs are associated with a higher mean age and mean SUVmax compared to benign PIUs.

  • 4

    A peripheral location of PIU is identified as a predictor of malignancy.

  • 5

    The study emphasizes the need for individualized clinical correlation when PIU is detected, especially with specific characteristics.

Original Source(s)

Prostatic incidental uptake on PET/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk

  • by Chiara Martinello, Cesare Michele Iacovitti, Andreea Marin, Slavko Tasevski, Alessio Rizzo, Marco Cuzzocrea, Gaetano Paone, Domenico Albano, Giorgio Treglia

  • June 22, 2026

Related Content

Ablating Satb1 reprograms the differentiation trajectory of exhausted CD8+ T subsets to enhance antitumor immunity

CCDC88C::PDGFRB-Rearranged Myeloid Neoplasm with Predominant Neutrophilia and Rapid Response to Imatinib: A Molecularly Defined Case Report

Spatial RNA velocity reveals cellular state transitions and prognostic markers in the melanoma microenvironment